REDWOOD CITY, Calif., Feb. 27, 2013 (GLOBE NEWSWIRE) -- myoscience, inc. is pleased to announce the addition of Bill Brodie to the team as VP, Global Sales and Marketing. Bill was most recently the Vice President of Global Sales at Solta Medical, where he grew revenues over $100 million in 5 years. Bill will be responsible for building out the sales and marketing infrastructure of myoscience, and leading the launch of the company's first product using their proprietary Focused Cold Therapy technology, iovera, a toxin-free option for the treatment of dynamic facial lines.
Clint Carnell, CEO of myoscience, says, "I am excited to have Bill on our team to lead the way to commercialize iovera in Europe. Bill is uniquely qualified to build a global team to promote and drive customer adoption of iovera as well as building demand for future products as we further develop the potential of Focused Cold Therapy beyond aesthetics."
"I'm excited about the potential to revolutionize the medical aesthetic industry with the launch of iovera. The technology that myoscience has developed will change the face of treatment of peripheral nerves across many fields, and I look forward to leading the company forward in both aesthetics and therapeutics. These are very exciting times," says Mr. Brodie.
myoscience's technology, Focused Cold Therapy™ delivers precise cold to peripheral nerve tissue. Nerves treated with this technology undergo a predictable period of dormancy, followed by complete restoration of function. iovera treats dynamic forehead lines immediately with results lasting up to 3 months. The treatment is designed for use in a physician's office and takes about 15 minutes. iovera will be first available in select centers of excellence before becoming more widely available across Europe throughout 2013.
For more information about iovera, visit www.myoscience.com.
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy TM, the standard of care for the treatment of peripheral nerve conditions. It is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13581
CONTACT: Alexandra Mack, myoscience inc. Tel: 00 1 650 421 0609 firstname.lastname@example.org